Total Payments
$414,988
2024 Payments
$67,677
Companies
26
Transactions
445
Medicare Patients
1,572
Medicare Billing
$746,321
Payment Breakdown by Category
Other$233,643 (56.3%)
Consulting$141,523 (34.1%)
Travel$29,743 (7.2%)
Food & Beverage$10,079 (2.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $197,913 | 80 | 47.7% |
| Consulting Fee | $141,523 | 55 | 34.1% |
| Travel and Lodging | $29,743 | 128 | 7.2% |
| Honoraria | $21,870 | 9 | 5.3% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $13,860 | 3 | 3.3% |
| Food and Beverage | $10,079 | 170 | 2.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | $96,205 | 83 | $0 (2023) |
| Deciphera Pharmaceuticals Inc. | $58,243 | 60 | $0 (2024) |
| Lilly USA, LLC | $35,389 | 55 | $0 (2017) |
| Eli Lilly and Company | $30,173 | 19 | $0 (2021) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $27,073 | 22 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $26,011 | 42 | $0 (2018) |
| Regeneron Healthcare Solutions, Inc. | $25,692 | 24 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $18,893 | 20 | $0 (2017) |
| E.R. Squibb & Sons, L.L.C. | $18,025 | 15 | $0 (2019) |
| Eisai Inc. | $16,131 | 24 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $67,677 | 78 | Deciphera Pharmaceuticals Inc. ($31,036) |
| 2023 | $11,044 | 26 | Deciphera Pharmaceuticals Inc. ($6,732) |
| 2022 | $40,423 | 37 | Boehringer Ingelheim Pharmaceuticals, Inc. ($13,148) |
| 2021 | $38,628 | 26 | Bayer HealthCare Pharmaceuticals Inc. ($12,572) |
| 2020 | $28,582 | 19 | Regeneron Healthcare Solutions, Inc. ($10,075) |
| 2019 | $86,441 | 76 | Bayer HealthCare Pharmaceuticals Inc. ($61,791) |
| 2018 | $51,642 | 51 | Novartis Pharmaceuticals Corporation ($20,011) |
| 2017 | $90,550 | 132 | Lilly USA, LLC ($35,389) |
All Payment Transactions
445 individual payment records from CMS Open Payments — Page 1 of 18
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | SpringWorks Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,550.00 | General |
| 12/18/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Food and Beverage | In-kind items and services | $25.67 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Consulting Fee | Cash or cash equivalent | $595.00 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Travel and Lodging | Cash or cash equivalent | $385.02 | General |
| Category: ONCOLOGY | ||||||
| 12/04/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $20.68 | General |
| Category: Oncology | ||||||
| 11/15/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Food and Beverage | In-kind items and services | $7.23 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $36.59 | General |
| Category: DESMOID TUMORS | ||||||
| 11/13/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $26.14 | General |
| Category: DESMOID TUMORS | ||||||
| 11/13/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $7.84 | General |
| Category: DESMOID TUMORS | ||||||
| 11/13/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $7.84 | General |
| Category: DESMOID TUMORS | ||||||
| 11/12/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Travel and Lodging | In-kind items and services | $348.25 | General |
| Category: DESMOID TUMORS | ||||||
| 11/12/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $135.00 | General |
| Category: DESMOID TUMORS | ||||||
| 11/06/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Consulting Fee | Cash or cash equivalent | $11,645.00 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Travel and Lodging | Cash or cash equivalent | $83.08 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Travel and Lodging | Cash or cash equivalent | $70.00 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Travel and Lodging | Cash or cash equivalent | $55.95 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Travel and Lodging | Cash or cash equivalent | $27.80 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Travel and Lodging | Cash or cash equivalent | $20.25 | General |
| Category: ONCOLOGY | ||||||
| 10/25/2024 | LANTHEUS MEDICAL IMAGING, INC. | — | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| 10/17/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Consulting Fee | Cash or cash equivalent | $595.00 | General |
| Category: ONCOLOGY | ||||||
| 10/10/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Travel and Lodging | In-kind items and services | $882.95 | General |
| Category: ONCOLOGY | ||||||
| 10/08/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,272.50 | General |
| Category: ONCOLOGY | ||||||
| 10/01/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $29.67 | General |
| 09/26/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Food and Beverage | In-kind items and services | $133.34 | General |
| Category: ONCOLOGY | ||||||
| 08/26/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $10,360.00 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 282 | 529 | $190,136 | $57,961 |
| 2022 | 3 | 247 | 535 | $199,323 | $62,262 |
| 2021 | 5 | 232 | 451 | $157,623 | $50,580 |
| 2020 | 29 | 811 | 17,992 | $2.3M | $575,519 |
Total Patients
1,572
Total Services
19,507
Medicare Billing
$746,321
Procedure Codes
42
All Medicare Procedures & Services
42 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 105 | 287 | $109,060 | $33,692 | 30.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 73 | 129 | $33,024 | $10,561 | 32.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 52 | 52 | $28,964 | $7,637 | 26.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 26 | 28 | $10,640 | $3,369 | 31.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 26 | 33 | $8,448 | $2,702 | 32.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 127 | 350 | $133,000 | $42,896 | 32.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 57 | 122 | $31,232 | $9,972 | 31.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 63 | 63 | $35,091 | $9,394 | 26.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 107 | 227 | $86,260 | $28,675 | 33.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 55 | 55 | $30,635 | $8,611 | 28.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 42 | 94 | $24,064 | $7,907 | 32.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 14 | 54 | $14,634 | $4,800 | 32.8% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2021 | 14 | 21 | $2,030 | $586.50 | 28.9% |
| J9312 | Injection, rituximab, 10 mg | Office | 2020 | 13 | 1,569 | $403,704 | $116,942 | 29.0% |
| J9145 | Injection, daratumumab, 10 mg | Office | 2020 | 12 | 2,484 | $454,572 | $106,351 | 23.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2020 | 34 | 5,340 | $309,720 | $80,370 | 25.9% |
| J2505 | Injection, pegfilgrastim, 6 mg | Office | 2020 | 19 | 23 | $198,030 | $74,445 | 37.6% |
| J9047 | Injection, carfilzomib, 1 mg | Office | 2020 | 11 | 2,404 | $283,672 | $71,485 | 25.2% |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2020 | 12 | 1,330 | $178,220 | $42,023 | 23.6% |
| J9041 | Injection, bortezomib (velcade), 0.1 mg | Office | 2020 | 13 | 541 | $94,134 | $19,322 | 20.5% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2020 | 93 | 139 | $130,660 | $16,380 | 12.5% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 62 | 75 | $18,750 | $7,043 | 37.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 48 | 63 | $27,342 | $6,731 | 24.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 46 | 83 | $26,809 | $5,978 | 22.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 13 | 45 | $12,235 | $4,136 | 33.8% |
About Dr. Mark Agulnik, MD
Dr. Mark Agulnik, MD is a Medical Oncology healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1164448734.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Agulnik, MD has received a total of $414,988 in payments from pharmaceutical and medical device companies, with $67,677 received in 2024. These payments were reported across 445 transactions from 26 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($197,913).
As a Medicare-enrolled provider, Agulnik has provided services to 1,572 Medicare beneficiaries, totaling 19,507 services with total Medicare billing of $746,321. Data is available for 4 years (2020–2023), covering 42 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Medical Oncology
- Location Los Angeles, CA
- Active Since 07/15/2006
- Last Updated 05/08/2024
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1164448734
Products in Payments
- Vitrakvi (Drug) $83,862
- QINLOCK (Drug) $53,079
- LIBTAYO (Biological) $32,607
- VOTRIENT (Drug) $24,492
- DARZALEX (Biological) $18,951
- OPDIVO (Biological) $18,025
- Halaven (Drug) $16,131
- Turalio (Drug) $14,572
- FYARRO (Drug) $10,980
- Stivarga (Drug) $6,665
- AYVAKIT (Drug) $5,740
- VIMSELTINIB (Drug) $4,569
- LYNPARZA (Drug) $3,450
- Non-Covered $2,560
- LIBTAYO (Drug) $1,300
- OGSIVEO (Drug) $756.58
- AFINITOR (Drug) $702.00
- FOUNDATIONONE LIQUID (Device) $700.00
- Fyarro (Drug) $453.59
- TURALIO (Drug) $400.71
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Los Angeles
Dr. Jacek Pinski, M.d, M.D
Medical Oncology — Payments: $882,931
Medical Oncology $882,931
Stephen Liu, Md, MD
Medical Oncology — Payments: $792,850
Medical Oncology $792,850
Matthew Rettig, Md, MD
Medical Oncology — Payments: $564,294
Medical Oncology $564,294
Dr. David Quinn, M.d, M.D
Medical Oncology — Payments: $304,638
Medical Oncology $304,638
Dr. David Tran, Md Phd, MD PHD
Medical Oncology — Payments: $131,074
Medical Oncology $131,074
Dr. Barbara Gitlitz, M.d, M.D
Medical Oncology — Payments: $68,433
Medical Oncology $68,433